FDA Approval Pathways: 510(k), PMA, and De Novo

The FDA does not have a single approval process for medical devices. It has three primary pathways, each designed for a different level of risk and novelty, and each with dramatically different cost, time, and evidence requirements. Choosing the wrong pathway is not just an administrative mistake — it can mean spending two years and several million dollars building a clinical evidence package that the agency was never going to accept for that product category.

The 510(k) pathway is the most commonly used route to market for medical devices in the United States. It is a clearance process, not an approval process — a distinction that matters legally and commercially. To clear a device through 510(k), the manufacturer must demonstrate that the new device is substantially equivalent to a legally marketed predicate device that is already on the market. Substantial equivalence does not mean identical. It means the new device has the same intended use and the same or different technological characteristics, and that any different characteristics do not raise new questions of safety and effectiveness.

Finding the right predicate is one of the most consequential early decisions in a device company's life. A strong predicate — one with the same intended use, similar risk profile, and a cleared classification — can make a 510(k) submission relatively straightforward. A weak predicate, or a product that has no adequate predicate, forces the company toward De Novo or PMA. Some founders discover this six months into development, after building a product whose intended use claims are broad enough that no predicate exists. Scoping your intended use claims is a regulatory strategy decision, not a marketing one.

The Premarket Approval (PMA) pathway applies to Class III devices — those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. Pacemakers, implantable cardioverter-defibrillators, and certain in vitro diagnostic tests are Class III. PMA requires valid scientific evidence — typically from well-controlled clinical investigations — that provides reasonable assurance of safety and effectiveness. The average PMA takes three to seven years and costs tens to hundreds of millions of dollars in clinical evidence generation. This is not a pathway most early-stage companies can self-fund.

The De Novo pathway was created for novel, low-to-moderate risk devices that have no valid predicate but do not require the full PMA level of evidence. When a company submits a De Novo request, it is asking FDA to create a new device classification with a set of special controls that, combined with general controls, provide reasonable assurance of safety and effectiveness. If granted, the De Novo decision itself becomes a predicate that future companies can use for 510(k) submissions. This is strategically important — the first company to receive De Novo clearance in a new device category effectively defines the regulatory standard for that space.

Device classification — Class I, II, or III — is the underlying framework that determines which pathway applies. Class I devices are low risk and subject to general controls only. Most are exempt from 510(k) requirements entirely. Class II devices are moderate risk and subject to both general controls and special controls, which are the performance standards, guidance documents, and post-market surveillance requirements specific to that device type. Class III devices are highest risk and require PMA unless they are reclassified. Understanding your device's classification code — the three-letter FDA product code — and the regulation number that governs it is the first piece of homework any regulatory strategy requires.

The Breakthrough Device Program is a separate designation, not a pathway, that is worth understanding. It is available to devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. Breakthrough designation gives a company priority review, more interactive communication with FDA during development, and the possibility of rolling review of completed sections before the full submission is ready. It does not lower the evidentiary standard, but it can dramatically compress the calendar. Companies pursuing novel devices in serious disease areas should evaluate Breakthrough designation early.